作者
Farnoosh Seirafianpour, Samaneh Mozafarpoor, Nima Fattahi, Afsaneh Sadeghzadeh‐Bazargan, Melika Hanifiha, Azadeh Goodarzi
发表日期
2020/7
来源
Dermatologic therapy
卷号
33
期号
4
页码范围
e13733
出版商
John Wiley & Sons, Inc.
简介
The world is facing a viral pandemic of a new coronavirus called COVID‐19. Pentoxifylline is a methyl‐xanthine derivative and it inhibits the phosphodiesterase IV (PDE IV). This drug is known for its unique features as an immunomodulatory and anti‐inflammatory agent, also it could have antiviral affects. This is a scoping review, in which all related articles on COVID‐19 and the probable benefits of Pentoxifylline against COVID‐19 pathogenesis, in Medline, Scopus, Web of Sciences, and Google Scholar up to 20 March 2020 with proper keywords including: pentoxifylline, Pentoxil, COVID‐19, coronavirus, treatment, anti‐inflammatory, immunomodulatory, antifibrosis, oxygenation, circulation, bronchodilator, ARDS, and organ failure. We found many confirmatory data on proper efficacy of pentoxifylline on controlling COVID‐19 and its consequences. The antiviral, anti‐inflammatory, anti‐oxidative, immune …
学术搜索中的文章
F Seirafianpour, S Mozafarpoor, N Fattahi… - Dermatologic therapy, 2020